Browse by author
Lookup NU author(s): Professor Michela GuglieriORCiD, Emerita Professor Katherine Bushby
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Duchenne muscular dystrophy (DMD) is the most common childhood muscular dystrophy and results from mutations in the dystrophin gene. Currently no treatment is available for this devastating condition. Standards of care have been improving and are spreading world-wide, prolonging survival and increasing quality of life, however management of symptoms and complications remains the only interventions that can currently be offered to patients.New and promising experimental strategies to address DMD have been developed over the last few years and some of them are in or are approaching clinical trials. Different therapeutic options are being investigated, ranging from mutation-specific treatments, including nonsense codon suppressors and exon skipping, to gene therapy using viral and nonviral vectors and cell-based approaches.Here we review the current status of molecular investigational treatments in DMD, with a particular focus on those compounds and strategies that are currently in clinical trials or are likely to approach clinical application in the near future. © 2010 Elsevier Ltd.
Author(s): Guglieri M, Bushby K
Publication type: Review
Publication status: Published
Journal: Current Opinion in Pharmacology
Year: 2010
Volume: 10
Issue: 3
Pages: 331-337
Print publication date: 29/04/2010
ISSN (print): 1471-4892
ISSN (electronic): 1471-4973
URL: http://dx.doi.org/10.1016/j.coph.2010.03.005
DOI: 10.1016/j.coph.2010.03.005
PubMed id: 20434401
